ACE inhibitors and AT1R blockers (sartans) are known to upregulate ACE2 [212,213,214] whilst the role of inhaled corticosteroids (ICS), which are used as first-line therapy of COPD in the combination with bronchodilators, is not very clear. The gene discussed is ACE2; the disease is chronic obstructive pulmonary disease.